-
Abstract Number: 1471
Sex-related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-analysis
-
Abstract Number: 1472
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
-
Abstract Number: 1473
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
-
Abstract Number: 1474
Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
-
Abstract Number: 1475
Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial
-
Abstract Number: 1476
Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis
-
Abstract Number: 1477
Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
-
Abstract Number: 1478
Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
-
Abstract Number: 1479
Effectiveness of B/tsDMARDs Including Ixekizumab Per Line of Therapy and Concomitant CsDMARDs in Psoriatic Arthritis: Real-World Data from a Prospective Observational Study
-
Abstract Number: 1480
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
-
Abstract Number: 1481
Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials
-
Abstract Number: 1482
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
-
Abstract Number: 1483
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
-
Abstract Number: 1484
A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
-
Abstract Number: 1485
Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins
- « Previous Page
- 1
- …
- 98
- 99
- 100
- 101
- 102
- …
- 181
- Next Page »